Glutaleap

Glutaleap Uses, Dosage, Side Effects, Food Interaction and all others data.

A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells. An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease . This oral formulation is marketed under the tradename Endari by Emmaus Medical.

Like other amino acids, glutamine is biochemically important as a constituent of proteins. Glutamine is also crucial in nitrogen metabolism. Ammonia (formed by nitrogen fixation) is assimilated into organic compounds by converting glutamic acid to glutamine. The enzyme which accomplishes this is called glutamine synthetase. Glutamine can then be used as a nitrogen donor in the biosynthesis of many compounds, including other amino acids, purines, and pyrimidines.

L-glutamine improves nicotinamide adenine dinucleotide (NAD) redox potential .

Glutaleap
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Glutaleap
Generic	L-Glutamine
L-Glutamine Other Names	Glutamic acid 5-amide, Glutamic acid amide, Glutamina, Glutamine, L-Glutamin, L-Glutamine, L-Glutaminsäure-5-amid, Levoglutamide
Weight	10gm, 20g
Type	Sachet, Solution For Infusion
Formula	C₅H₁₀N₂O₃
Weight	Average: 146.1445 Monoisotopic: 146.069142196
Groups	Approved, Investigational, Nutraceutical
Therapeutic Class
Manufacturer	Scutonix Lifesciences Pvt Ltd
Available Country	India
Last Updated:	September 19, 2023 at 7:00 am

Uses

Glutaleap is an amino acid commonly found as a component in total parenteral nutrition.

Used for nutritional supplementation, also for treating dietary shortage or imbalance.

Used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older .

Glutaleap is also used to associated treatment for these conditions: Osteoporosis, Acute Complications of Sickle Cell Disease

How Glutaleap works

Supplemental L-glutamine's possible immunomodulatory role may be accounted for in a number of ways. L-glutamine appears to play a major role in protecting the integrity of the gastrointestinal tract and, in particular, the large intestine. During catabolic states, the integrity of the intestinal mucosa may be compromised with consequent increased intestinal permeability and translocation of Gram-negative bacteria from the large intestine into the body. The demand for L-glutamine by the intestine, as well as by cells such as lymphocytes, appears to be much greater than that supplied by skeletal muscle, the major storage tissue for L-glutamine. L-glutamine is the preferred respiratory fuel for enterocytes, colonocytes and lymphocytes. Therefore, supplying supplemental L-glutamine under these conditions may do a number of things. For one, it may reverse the catabolic state by sparing skeletal muscle L-glutamine. It also may inhibit translocation of Gram-negative bacteria from the large intestine. L-glutamine helps maintain secretory IgA, which functions primarily by preventing the attachment of bacteria to mucosal cells. L-glutamine appears to be required to support the proliferation of mitogen-stimulated lymphocytes, as well as the production of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma). It is also required for the maintenance of lymphokine-activated killer cells (LAK). L-glutamine can enhance phagocytosis by neutrophils and monocytes. It can lead to an increased synthesis of glutathione in the intestine, which may also play a role in maintaining the integrity of the intestinal mucosa by ameliorating oxidative stress. The exact mechanism of the possible immunomodulatory action of supplemental L-glutamine, however, remains unclear. It is conceivable that the major effect of L-glutamine occurs at the level of the intestine. Perhaps enteral L-glutamine acts directly on intestine-associated lymphoid tissue and stimulates overall immune function by that mechanism, without passing beyond the splanchnic bed.

The exact mechanism of L-glutamine's effect on NAD redox potential is unknown but is thought to involve increased amounts of reduced glutathione made available by glutamine supplementation . This improvement in redox potential reduces the amount of oxidative damage which sickle red blood cells are more susceptible to. The reduction in cellular damage is thought to reduce chronic hemolysis and vaso-occlusive events.

Toxicity

Doses of L-glutamine up to 21 grams daily appear to be well tolerated. Reported adverse reactions are mainly gastrointestinal and not common. They include constipation and bloating. There is one older report of two hypomanic patients whose manic symptoms were exacerbated following the use of 2 to 4 grams daily of L-glutamine. The symptoms resolved when the L-glutamine was stopped. These patients were not rechallenged, nor are there any other reports of this nature.

The most common adverse effects observed in clinical trials of Endari were constipation (21%), nausea (19%), headache (18%), abdominal pain (17%), cough (16%), extremity pain (13%), back pain (12%), and chest pain (12%) .

Food Interaction

Take with food. Endari (L-glutamine) oral powder should be mixed with 8oz of water or 4-6 oz of food at room temperature or colder, then consumed.

Volume of Distribution

Volume of distribution is 200 mL/kg after intravenous bolus dose .

Elimination Route

Absorption is efficient and occurs by an active transport mechanism. Tmax is 30 minutes after a single dose . Absorption kinetics following multiple doses has not yet been determined.